Peptides, especially constrained and cyclic peptides, are receiving increasing attention in drug discovery. Their advantages are small size, intracellular activity, as well as high selectivity of binding to the target molecule, and the ability to effect interactions between proteins. New synthetic biology technologies enable the production of large constrained peptide libraries and the rapid and efficient selection of peptides with high target binding affinity. The company PeptiDream, whose technology is described in this diploma work, has already established an effective technology for obtaining and improving constrained peptides, and a number of products are already entering clinical trials.
|
